Latest News
Quidel’s Sofia® 2 Point-of-Care Immunoassay Analyzer Receives Multiple Awards from Good Design Australia®’s 2017 Good Design Awards®
SAN DIEGO--(BUSINESS WIRE)--Jun. 22, 2017--
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic
testing solutions, cellular-based virology assays and molecular
diagnostic systems, announced today that its Sofia 2 point-of-care
immunoassay analyzer has received special recognition from Good Design
Australia, an international design promotion organization responsible
for managing Australia’s annual Good Design Awards and other signature
design events.
Careers
Are you a determined, optimistic, team player? Quidel is looking for talented innovators who want to be part of revolutionizing medical diagnostics.
Support
We appreciate your efforts to improve patient care, physician services, and laboratory efficiency. We know that you will appreciate the value that Quidel brings in delivering diagnostics that do not sacrifice accuracy or ease-of-use. Please explore this site for helpful resources and how you can contact us for further support.